drugset / Trial / NCT00002168

A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

NCT00002168

Completed 200 enrolled Bristol-Myers Squibb
Parallel-groupTreatment

Summary

The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs. One drug combination is stavudine (d4T) plus didanosine (ddI) plus Crixivan. The other combination is Retrovir (AZT) plus Epivir (3TC) plus Crixivan.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Didanosine Small molecule
Subject INDINAVIR ANHYDROUS Other / unclassified
Subject Lamivudine Other / unclassified
Subject Stavudine Other / unclassified
Subject Zidovudine Small molecule